115 related articles for article (PubMed ID: 12490276)
41. Successful treatment with rituximab of an Epstein-Barr virus-associated leiomyosarcoma occurring after liver transplantation.
Jericho H; Weinstein J; Melin-Aldana H; Leuer KC; Wyers M; Alonso EM; Ekong UD
J Pediatr Gastroenterol Nutr; 2014 Jan; 58(1):e2-4. PubMed ID: 24378523
[No Abstract] [Full Text] [Related]
42. Low viral load post-transplant lymphoproliferative disease localized within the tongue.
Henry DD; Hunger SP; Braylan RC; Dharnidharka VR
Transpl Infect Dis; 2008 Dec; 10(6):426-30. PubMed ID: 18657087
[TBL] [Abstract][Full Text] [Related]
43. Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation.
Worth A; Conyers R; Cohen J; Jagani M; Chiesa R; Rao K; Goulden N; Veys P; Amrolia PJ
Br J Haematol; 2011 Nov; 155(3):377-85. PubMed ID: 21910716
[TBL] [Abstract][Full Text] [Related]
44. Rapidly progressive Epstein-Barr virus-associated lymphoproliferative disorder unpredictable by weekly viral load monitoring.
Wakabayashi S; Ohashi K; Hanajiri R; Kobayashi T; Yamashita T; Akiyama H; Sakamaki H
Intern Med; 2010; 49(10):931-5. PubMed ID: 20467179
[TBL] [Abstract][Full Text] [Related]
45. Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era.
Ghobrial IM; Habermann TM; Ristow KM; Ansell SM; Macon W; Geyer SM; McGregor CG
Leuk Lymphoma; 2005 Feb; 46(2):191-6. PubMed ID: 15621801
[TBL] [Abstract][Full Text] [Related]
46. Dynamics of Epstein-Barr viral load after hematopoietic stem cell transplantation and effect of preemptive rituximab therapy.
Raberahona M; Wackenheim C; Germi R; Carré M; Bulabois CE; Thiébaut A; Lupo J; Semenova T; Cahn JY; Morand P; Epaulard O
Transpl Infect Dis; 2016 Dec; 18(6):889-895. PubMed ID: 27696681
[TBL] [Abstract][Full Text] [Related]
47. Epstein-Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course.
Oertel S; Trappe RU; Zeidler K; Babel N; Reinke P; Hummel M; Jonas S; Papp-Vary M; Subklewe M; Dörken B; Riess H; Gärtner B
Ann Hematol; 2006 Jul; 85(7):478-84. PubMed ID: 16586109
[TBL] [Abstract][Full Text] [Related]
48. Outcome of Rituximab-Based Treatment for Post-Transplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience.
Zhu CY; Zhao SS; Wang XK; Wang L; Wang FY; Fang S; Liu ZX; Guan LX; Liu YC; Ding Y; Dou LP; Wang LL; Gao CJ
Ann Transplant; 2019 Apr; 24():175-184. PubMed ID: 30940797
[TBL] [Abstract][Full Text] [Related]
49. Diagnosis and treatment of post-transplantation lymphoproliferative disorder in pediatric heart transplant patients.
Schubert S; Abdul-Khaliq H; Lehmkuhl HB; Yegitbasi M; Reinke P; Kebelmann-Betzig C; Hauptmann K; Gross-Wieltsch U; Hetzer R; Berger F
Pediatr Transplant; 2009 Feb; 13(1):54-62. PubMed ID: 18518912
[TBL] [Abstract][Full Text] [Related]
50. Prompt diagnosis and management of Epstein-Barr virus-associated post-transplant lymphoproliferative disorder and hemophagocytosis: A dreaded complication in a post-liver transplant child.
Jha B; Mohan N; Gajendra S; Sachdev R; Goel S; Sahni T; Raina V; Soin A
Pediatr Transplant; 2015 Nov; 19(7):E177-80. PubMed ID: 26184957
[TBL] [Abstract][Full Text] [Related]
51. Post-transplant lymphoproliferative disease and other Epstein-Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction.
Kinch A; Oberg G; Arvidson J; Falk KI; Linde A; Pauksens K
Scand J Infect Dis; 2007; 39(3):235-44. PubMed ID: 17366054
[TBL] [Abstract][Full Text] [Related]
52. Epstein-Barr virus load in transplant patients: Early detection of post-transplant lymphoproliferative disorders.
Fellner MD; Durand KA; Solernou V; Bosaleh A; Balbarrey Z; García de Dávila MT; Rodríguez M; Irazu L; Alonio LV; Picconi MA
Rev Argent Microbiol; 2016; 48(2):110-8. PubMed ID: 27157146
[TBL] [Abstract][Full Text] [Related]
53. Lymphoproliferative disorder of the airway of an adolescent without immunodeficiency.
Boesch RP; Daines M; Kaul A; Cotton R; Amin R
Int J Pediatr Otorhinolaryngol; 2005 Nov; 69(11):1591-4. PubMed ID: 15963576
[TBL] [Abstract][Full Text] [Related]
54. Epstein-Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation.
Zallio F; Primon V; Tamiazzo S; Pini M; Baraldi A; Corsetti MT; Gotta F; Bertassello C; Salvi F; Rocchetti A; Levis A
Clin Transplant; 2013; 27(4):E491-7. PubMed ID: 23781897
[TBL] [Abstract][Full Text] [Related]
55. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD).
Oertel SH; Verschuuren E; Reinke P; Zeidler K; Papp-Váry M; Babel N; Trappe RU; Jonas S; Hummel M; Anagnostopoulos I; Dörken B; Riess HB
Am J Transplant; 2005 Dec; 5(12):2901-6. PubMed ID: 16303003
[TBL] [Abstract][Full Text] [Related]
56. Sustained response to intrathecal rituximab in EBV associated Post-transplant lymphoproliferative disease confined to the central nervous system following haematopoietic stem cell transplant.
Bonney DK; Htwe EE; Turner A; Kelsey A; Shabani A; Hughes S; Hughes I; Wynn RF
Pediatr Blood Cancer; 2012 Mar; 58(3):459-61. PubMed ID: 21584931
[TBL] [Abstract][Full Text] [Related]
57. EBV-positive mucocutaneous ulcer in organ transplant recipients: a localized indolent posttransplant lymphoproliferative disorder.
Hart M; Thakral B; Yohe S; Balfour HH; Singh C; Spears M; McKenna RW
Am J Surg Pathol; 2014 Nov; 38(11):1522-9. PubMed ID: 25007145
[TBL] [Abstract][Full Text] [Related]
58. Posttransplant lymphoproliferative disorder in a lung transplant recipient.
Tamai K; Koyama T; Saga T; Umeoka S; Aoyama A; Hanaoka N; Fukuse T; Wada H; Tachibana M; Togashi K
J Thorac Imaging; 2005 Nov; 20(4):280-3. PubMed ID: 16282905
[TBL] [Abstract][Full Text] [Related]
59. EBV-induced polymorphic lymphoproliferative disorder of the iris after heart transplantation.
Rohrbach JM; Kröber SM; Teufel T; Kortmann RD; Zierhut M
Graefes Arch Clin Exp Ophthalmol; 2004 Jan; 242(1):44-50. PubMed ID: 14663590
[TBL] [Abstract][Full Text] [Related]
60. EBV lymphoproliferative disease of host origin after haploidentical stem cell transplantation.
Kasow KA; Leung W; Horwitz EM; Woodard P; Handgretinger R; Hale GA
Pediatr Blood Cancer; 2007 Nov; 49(6):869-72. PubMed ID: 16421900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
